market perform
reason report
higher convict braf support upgrad pt
bottom line upgrad rate arri share
outperform market perform arri key valu driver mek
braf inhibitor binimetinib encorafenib respect
current late stage develop patient braf colorect
cancer braf melanoma addit binimetinib
evalu earli stage combin trial part trial collabor
mp op mp updat data present
weekend gastrointestin cancer symposium asco-gi
safety-lead-in portion arri beacon-crc phase trial
patient braf indic treatment durat
binimetinib/encorafenib combin henc potenti sale
opportun indic could significantli larger
previous anticip roughli us base estim
particular consid arri also plan develop
front-lin braf near futur base updat
result think likelihood success phase trial protocol
amend henc faster path market origin anticip
increas significantli competit arri smaller
braf melanoma market intens vs braf updat
analysi indic binimetinib/encorafenib could potenti benefit
recent uptick mek/brafi volum sale growth
us launch pend fda approv
yet valu opportun binimetinib combin
agent evalu earli stage trial think arri
sever shot goal could creat addl upsid particularli
intrigu parpi combin part arri recent collabor
first data like emerg updat price
target consist braf braf
melanoma selumetinib royalti cash
share outstand mil oct
compani inform leerink partner llc research
revenu mm ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rx trend deriv im health
arri leader develop small molecul tyrosin kinas inhibitor tki use structure-
guid drug develop platform valu driver stock compani mek
braf inhibitor binimetinib encorafenib respect current late stage
develop patient braf colorect cancer braf melanoma base
analysi braf market believ opportun bini/enco braf
larger roughli us current assum investor potenti earli unblind
on-going beacon- trial line braf earli repres key
catalyst within month believ probabl success trial high longer
term believ bini/enco could also develop front line braf us approv
bini/enco base posit result columbu phase trial like
expect investor think braf melanoma market could grow faster
current assum despit increas use io agent base analysi due
dilig medacorp kol believ binimetinib/encorafenib differenti
current approv mek/braf inhibitor given mek/braf inhibitor approv
novarti nv mp roch well entrench clinic practic launch assumpt
alreadi reflect conserv scenario assum peak market share stage iv braf
melanoma patient longer term believ particular mek inhibitor play central role
tumor biolog sever commerci opportun exist binimetinib combin
agent complementari mechan arri start sever trial collabor
includ mp op mp potenti maxim potenti
binimetinib repres sourc upsid stock current valuat
braf opportun bigger expect base updat bacon- safeti
lead-in asco-gi weekend arri present updat result safety-lead-in sli
portion on-going beacon- phase trial braf patient
recal beacon-crc current evalu arri encorafenib binimetinib combin
erbitux braf colorect cancer patient sli data previous present esmo
alreadi indic tripl combin efficaci orr doublet
encorafenib erbitux alon orr new data present asco-gi indic
respons deepen follow-up overal line patient
includ complet remiss previous inform progression-fre
surviv also disclos first time indic impress median
month durat therapi month compar prior mpf assumpt
month current standard care month mpf orr think
increas probability-of-success phase trial evalu encorafenib
cetuximab without binimetinib comparison cetuximab irinotecan base therapi
line cap braf
plan trial amend could potenti acceler path market recent met
manag indic beacon-crc trial enrol well enrol
complet expect end base impress sli data gener date
management engag discuss fda goal amend phase trial protocol
incorpor interim analysi exampl base respons rate orr could
potenti reduc to-market timelin year base estim approv possibl
vs base current os endpoint given special protocol assess
spa agreement alreadi place fda discuss may oner hand
think like arri therapi obtain breakthrough therapi design btd base
sli data could acceler fda-interact arri manag also note
plan evalu potenti design registr trial front-lin braf
set arri also note interest explor studi adjuv set updat
braf market model incorpor month treatment durat line
also includ probabl adjust estim front-lin braf think
justifi base impress data gener thu far across sli phase ii studi
updat un-adjust us peak sale estim
previous assum po po respect
braf melanoma market continu grow despit io competit believ us-
approv binimetinib/encorafenib braf melanoma june pdufa date wide
expect base result phase columbu trial histor hesit
assign much valu indic given increas use io agent melanoma arri
market posit among mek/braf inhibitor kol feedback updat analysi
prescript sale trend howev indic mek/brafi market continu
grow even acceler us rx grow annual last month
recent quarter gross sale us grow im think
dynam posit arri plan launch us pend approv
current conserv model peak market share arri metastat melanoma
increas overal treat patient growth ramp result updat us peak sale
forecast previous arri best-in-class efficaci profil
better toler key market messag goal gain share increas
durat therapi current use agent
meki combo sourc upsid parp intrigu view result
rhhbi phase trial could potenti valid meki hypothesi
think probability-of-success rhhbi trial modest think downsid
arri limit upsid could signific phase i/ii trial collabor one
one current evalu combin binimetinib either keytruda
opdivo yervoy patient ra mss trial initi
respect intrigu view recent announc collabor
part collabor announc arri collabor
phase ib clinic trial explor combin binimetinib avelumab talazoparib across
variou tumor type includ non-smal cell lung cancer nsclc pancreat cancer
addit indic explor later stage recent scientif studi publish scienc
translat medicin may highlight find particular kra mutant tumor
highli sensit parpi meki/erki combin vitro anim model
studi highlight potenti meki revers resist parpi note
combin activ cell without alter potenti indic broad util
combin
model chang forecast revenu expect expir
binimetinib composit matter patent includ year hatch-waxman extens use
discount rate similar commerci near-commerci stage compani
coverag includ binimetinib encorafenib sale
braf melanoma braf forecast well probability-adjust estim
selumetinib royalti current valu molecul arri pipelin
includ inhibitor inhibitor recent transfer
subsidiari potenti royalti out-licens molecul
consid upsid valuat updat price target consist braf
braf melanoma selumetinib royalti cash
safeti lead-in phase ii data comparison
clinic efficaci treatment patient braf mcrc prior
us prescript volum mek/braf inhibitor continu grow despit
increas use io agent melanoma
us sale mek/braf inhibitor re-acceler recent quarter
mek/braf inhibitor net sale growth driven predominantli row
valu arri share month base discount cash flow analysi
use discount rate similar commerci near-commerci stage compani
coverag termin growth rate appli probability-
adjust forecast binimetinib encorafenib selumetinib royalti
emerg biotech compani arri face signific clinic regulatori develop
risk well commerci risk arri also face execut risk financi risk
compani may addit financ need turn cash flow posit
arri mm
licens mileston revenu
partner program
regain binimetinib
total expens
arri bs cf mm
chang
oper
invest
financ
sec file leerink partner estim
us product sale mm
royalti mm
product sale p/w mm
royalti p/w mm
product sale p/w mm
royalti p/w mm
number patient encorafenib combo line
number patient encorafenib combo line
number patient encorafenib combo line
durat treatment month line
durat treatment month line
durat treatment month line
monthli cost treatment net
number patient adv/m
number adv/m patient line therapi
number braf /kra wt patient line therapi
treat encorafenib cetuximab w/ oe w/o bini
number adv/m patient elig line therapi
number braf /kra wt patient line therapi
number elig pt arri combo line therapi
treat encorafenib/binimetinib/cetuximab arri
number adv/m patient elig line therapi
number braf patient line therapi
number elig pt arri combo line therapi
treat encorafenib/binimetinib/cetuximab arri
total number patient system line therapi
total number metastat braf patient line
total patient mek/braf inhibitor
treat mek/braf inhibitor
treat
trear
patient treat mek/braf inhibitor
patient treat mek/braf inhibitor
monthli net cost therapi
durat treatment line month
durat treatment line month estimate
